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ABSTRACT 
Objective: To study the clinical profile and prescription pattern of drugs in the treatment of osteoporosis in a tertiary care centre in Karnataka, India. 
Methods: This was a retrospective study carried out in a multi-speciality tertiary care hospital in Karnataka. Information was collected from case record 
forms of 100 patients of osteoporosis during a 12 mo tenure regarding various signs and symptoms they presented with and treatment provided. 
Results: Majority of the subjects were females (90%). Low back ache was the most common presenting symptom. There was an increase in mean 
calcium (8.84±8.32 mg/dl) and phosphorus levels (2.45±1.83 mg/dl) as compared to baseline at the follow up visit. Vitamin D and calcium 
supplementation were the most commonly prescribed medications followed by analgesics, calcitonin and bisphosphonates. A total of 77 adverse 
reactions were reported, gastritis being the commonest one. 
Conclusion: Vitamin D and Calcium supplements were more commonly prescribed than specific anti osteoporotic medications. 
Keywords: Low back ache, Bisphosphonates, Vitamin D, Calcium, Prescribing trends. 
 
INTRODUCTION 
Osteoporosis is a major health problem, especially in elderly 
populations worldwide. It is commonly associated with fragility 
fractures at the hip, spine, and wrist. The World Health Organisation 
(WHO) ranks osteoporosis as a major global healthcare problem, 
second to cardiovascular diseases. WHO defines osteoporosis as a 
bone mineral density (BMD) of 2.5 standard deviations or more below 
the mean peak bone mass (average of young, healthy adults) as 
measured by dual-energy X-ray absorptiometry [1]. Although reliable 
epidemiological data is lacking in India, there were approximately 26 
million osteoporosis patients in 2003 with the numbers projected to 
increase to about 36 million by 2013 [2]. In 2013, a total of about 50 
million people in India were either osteoporotic (T-score lower than–
2.5) or had low bone mass (T-score between −1.0 and −2.5) [3]. 
The pathogenesis of osteoporosis largely remains descriptive [4]. 
Imbalance between bone resorption and bone formation is the 
underlying mechanism by which osteoporosis occurs. Decrease in 
bone mass and an increase in fragility can occur because of failure to 
achieve optimal peak bone mass, bone loss caused by increased bone 
resorption, or inadequate replacement of lost bone as a result of 
decreased bone formation.  
Osteoporosis is often called the "silent disease" because bone loss 
occurs without any overt symptoms for a long period. In many cases, 
the first "symptom" is a broken bone. Osteoporotic fractures are also 
known as fragility fractures as they occur in those situations where 
healthy people would not normally break a bone. Typical fragility 
fractures occur in the vertebral column, rib, hip and wrist. 
Treatment of osteoporosis involves management of osteoporosis 
associated fractures, universal prevention measures, and medical 
treatment of the underlying disease. There is a range of anti-
resorptive or anabolic options like bisphosphonates, calcitonin, 
teriparatide that are available for the prevention of osteoporotic 
fractures. Appropriate symptomatic treatment in the form of 
analgesics and muscle relaxants may also be initiated. All 
pharmacological management strategies for the prevention and 
treatment of osteoporosis also include recommendations for 
adequate calcium and vitamin D supplementation [5]. 
As human life span is gradually increasing, more and more elderly 
people are being treated for primary and secondary osteoporosis over 
increasing periods of time. In the absence of specific guidelines for the 
treatment of osteoporosis and with the availability of a wide variety of 
drugs in the market, treatment of individuals has become more of a 
trial and error practice. Most clinicians employ change in serum 
calcium and phosphorus levels as the means to monitor success/ 
failure of osteoporosis therapy.  
Since there are no standard protocols, followed worldwide for the 
treatment of osteoporosis, more number of studies are required to 
find the most effective drugs for treating osteoporosis. In view of this, 
the present study was planned to investigate the clinical profile and 
prescribing patterns in patients of osteoporosis. 
MATERIALS AND METHODS 
This was a retrospective study carried out in a multi-speciality 
tertiary care hospital in Karnataka. It was carried out over a 12 mo 
period between January 2012 and December 2012.  
Inclusion criteria 
- Patients of either sex diagnosed with generalized osteoporosis. 
Exclusion criteria 
- Patients diagnosed with osteoporosis associated with malignancies. 
- Patients with localised osteoporosis. 
After obtaining clearance from the Institutional Ethics Committee 
(IEC), the hospital record files of 100 patients of osteoporosis 
satisfying the above inclusion criteria were analysed. The following 
details were collected  
• Demography (age, gender) 
• Clinical features at the time of presentation.  
• Baseline investigations like serum calcium, phosphorus, Alkaline 
Phosphatase (ALP). 
• Concomitant diseases if any. 
• Drugs prescribed for treatment of osteoporosis. 
• Concomitant medications, if any. 
• Adverse effects that occurred in patients and measures taken to 
treat them. Causality assessment was done using WHO causality 
term assessment criteria. 
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• Serum calcium and phosphorus levels after 3 mo of treatment. 
Data was further analysed using SPSS version 20. Analysis was done 
using descriptive statistics. Calcium and phosphorus levels were 
measured before and 3 mo after the start of therapy. Mean change in 
calcium and phosphorus levels was reported. Adverse drug 
reactions (ADRs), if any, were also reported. 
RESULTS AND DISCUSSION 
Of the 100 study subjects, 90 were females.  
 
 
Fig. 1: Age groups in the study population 
 
 
Fig. 2: Clinical features in the study population 
 
Fig. 3: T score values in study population 
 
The most frequently prescribed dose range for vitamin D was 10-15 µg 
(63.92%) followed by 15-20 µg (27.84%) and 20-30 µg (8.24%). 
Calcium was most commonly prescribed in the dose range of 625-
1000 mg (49.48%) followed by 200-500 mg (27.84%), 1200-1825 mg 
(10.31%) and 2000-2500 mg (12.37%). Paracetamol 650 mg daily was 
the most commonly prescribed oral analgesic (58.75%) followed by 
tramadol 75 mg (50%) and aceclofenac 200 mg (25%).  
Tramadol plus paracetamol combination was the most commonly 
prescribed topical analgesic in 72.72% of the study subjects. The most 
commonly prescribed muscle relaxants was thiocolchicoside (62.96%) 
and tizanidine (37.04%).  
Alendronate were the most commonly prescribed bisphosphonate 
(55.56%). It was either prescribed as once weekly or once daily dose. 
Ibandronic acid was the other commonly prescribed bisphosphonate 
given to 44.44% of the study population either as once daily or once 
monthly dosing. A total of 77 ADRs were reported in 53 out of the total 
100 study subjects. This included gastritis (64.15%), sedation 
(22.64%), vomiting (20.75%), fatigue (20.75%), constipation 
(11.32%) and maculopapular rash (5.66%). None of the ADRs were 
serious or required discontinuation of the suspected drug. All the 
ADRs were classified as “possible” according to WHO causality term 
assessment criteria. 
 
Table 1: Distribution of calcium and phosphorus levels in study population 
 Calcium levels Phosphorus levels 
 Reduced Normal Increased Reduced Normal Increased 
Before treatment 25 74 1 2 80 18 
After treatment 0 70 30 1 72 27 
There was an increase in mean calcium and phosphorus levels as compared to baseline at the follow up visit (3 mo after initiation of therapy) as 
shown in table 2. 
 
Table 2: Mean and percentage change in calcium and phosphorus levels 
Parameter At baseline visit* At follow UP visit* Percentage change in levels** 
Calcium level 8.91±0.60 9.81±0.58 8.84±8.32 
Phosphorus level 3.74±0.61 3.76±0.57 2.45±1.83 
*All values expressed in mean±SD (mg/dl), ** All values in mean±SD 
 
Table 3: Concomitant diseases and medications in the study population 
Parameter Males Females Total 
Concomitant diseases    
Hypertension 6 34 40 
Diabetes mellitus 5 18 23 
Osteoarthritis 5 8 13 
Rheumatoid arthritis 1 4 5 
Concomitant medications    
Multivitamins 10 70 80 
Proton pump inhibitors 10 64 74 
Antihypertensives 6 36 42 
Oral hypoglycaemic agents 5 19 24 
Steroids 3 16 19 
Pregabalin 8 10 18 
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Table 4: Prescription pattern of various drugs in osteoporosis 
Drug class Percentage of patients (%) 
 Vitamin D 




















The present study assessed the clinical profile and various 
prescription patterns for 100 patients diagnosed with osteoporosis. 
Majority of the patients were in the 51-60 y age groups with the mean 
age of the study population being 62.42±13.11 y. This is in accordance 
with studies which have shown peak incidence of osteoporosis in India 
at the age of 50-60 y, as compared to 70-80 y in the West [6, 7]. The 
present study showed a female preponderance with male: female ratio 
being 1: 9. This data, although in unison with data available from 
studies in western populations, is in contradiction with studies done 
earlier in Indian populations which show a male predominance [8, 9]. 
The traditional belief that men are more commonly affected in India 
could be related to men seeking and getting better medical attention 
[10]. However, recent studies conducted in India show a reversal of 
the sex ratio in patients affected with osteoporosis with the numbers 
being a little tilted towards females [11]. 
Low backache, which could be a result of vertebral fractures or 
compression, was the most common presentation in the current 
study seen in 83% of the patients. Prevalence data from population 
based studies conducted worldwide indicate a substantial variation 
in overall prevalence ranging from 10% to 25% in women and from 
10% to 27% in men [12-14]. 
The trend in calcium, phosphorus and serum ALP levels was similar 
to the results of another study done in South India measuring serum 
calcium, phosphorus and ALP levels in patients diagnosed with 
osteopenia and osteoporosis. 
Hypertension was the most common comorbidity seen in a little over 
half the study population (52.63%). In an earlier report to study the 
association between hypertension and osteoporosis, women with 
hypertension were found to be affected more frequently by 
osteoporosis (33.2 vs. 23.3 %), and higher prevalence, of hypertension 
seen among women with osteoporosis (32.2 vs. 22.5 %) [16]. 
Serum levels of calcium, phosphorus, 
and ALP are insensitive for diagnosing osteoporosis [15]. 
Knowledge about concomitant medications is important as certain 
drugs increase the risk of osteoporosis in the long run. 
Glucocorticoid-induced osteoporosis is the most common form of 
secondary osteoporosis. Glucocorticoids can increase apoptosis of 
osteoblasts thereby leading to bone loss. Glucocorticoids, which are 
taken on a long-term basis by an estimated 1% of the Indian adult 
population, especially the elderly, is a contributing factor to 
osteoporosis in India [17]. Out of the 24 subjects being prescribed 
oral hypoglycaemic agents, thiazolidinediones like pioglitazone was 
prescribed in 11 subjects (45.83%). This is of significance since 
these drugs are selective agonists of peroxisome proliferator-
activated receptor-γ which in turn decrease osteo blastogenesis 
[18]. Proton pump inhibitors (PPIs) decrease intestinal calcium 
absorption thereby increasing bone resorption. PPIs decrease BMD 
at the lumbar spine and hip, and increase the risk of vertebral and 
non vertebral fragility fractures, depending on the drug dose and 
duration of therapy [19]. 
The National Institute of Health (NIH), USA recommends vitamin D 
600 IU (15 µg) daily for men and women 19 to 70 y old and 800 IU (20 
µg) daily for men and women 71 y and older. In the present study, 
majority of the subjects (63.92%) were prescribed a daily dose 
ranging from 10-15 µg which was much less than the recommended 
dosage. Supplementation with vitamin D has been shown to improve 
musculoskeletal function and reduce the risk of falling in elderly 
women. Twenty-five trials that randomized women to vitamin D with 
or without calcium and measured bone density or fracture for at least 
one year revealed a 37% reduction in vertebral fractures [20]. 
The NIH recommends a Recommended Dietary Allowance (RDA) of 
1000 mg/day for individuals 19-50 y of age and men 51-70 y and 
1200 mg/day for women 51-70 y and all individuals>70 y of age for 
calcium. In the present study almost half the study population 
(49.48%) received calcium supplementation in the range of 625-
1000 mg/day and 27.84% of the population received 200-500 
mg/day. Thus most of the subjects received an inadequate dose of 
calcium every day. 22% of the patients received calcium 
supplementation>1200 mg/day. A meta-analysis of 29 studies, with 
over 63,000 individuals analysed, concluded that best effect in 
patients suffering with osteoporosis was seen with minimum doses 
of 1200 mg of calcium and 800 units of vitamin D daily [21]. 
Bisphosphonates were prescribed in only 18% of the patients in the 
present study. There has been a decline in the prescription rate of 
bisphosphonates due to the development of adverse reactions like 
gastritis and availability of better anti osteoporotic drugs [22]. 45% 
of the patients in the present study were prescribed calcitonin in the 
form of nasal spray. In a meta-analysis comprising of fourteen 
double-blind, placebo-controlled trials that evaluated the analgesic 
efficacy of calcitonin for osteoporosis-related vertebral fracture 
pain, thirteen studies demonstrated statistically significant 
improvement in pain or function in calcitonin-treated patients [23]. 
Serum calcium levels had increased from 8.91±0.60 mg/dl at baseline to 
9.81±0.58 mg/dl with a percentage increase of 8.84 % from baseline to 
follow up. As compared to 25 subjects, with calcium levels below normal 
at baseline visit, none of the subjects had a similar serum calcium level at 
follow up visit. This is attributed to the calcium and vitamin D 
supplementation along with other drugs like teriparatide.  
Although adverse drug reactions, as reported, as reported in the case 
files of the study subjects were noted down, these could not pin 
point a particular anti-osteoporotic medication as the cause of the 
ADR. Gastrointestinal side effects including gastritis, vomiting and 
constipation constituted the major spectrum of ADRs. This could be 
attributed to bis phosphonate therapy as shown by a study 
conducted by van den Bergh JPW et al. [24]. However, no literature 
reports are available regarding the adverse event profile of the 
various drugs used in osteoporosis. 
There were a few limitations in the present study. One of them is the 
non-availability of T-score values at follow up visit. T-score data would 
have helped in monitoring the efficacy of anti osteoporotic drugs 
better. Since data from only one follow up visit was available, the long 
term effects of anti osteoporotic medications could not be determined. 
CONCLUSION 
Osteoporosis, though one of the most common diseases affecting 
both elderly men and women, is also one of the most neglected 
diseases. Lack of overt symptoms in the initial stages of the disease, 
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unavailability of cheaper diagnostic tools to aid in early diagnosis 
and lack of consensus among physicians, on a common treatment 
regime, makes the situation grim. In the present study, calcium and 
vitamin D supplementation, albeit given to almost all the patients, 
the dose was much lesser than the RDA fixed for these nutrients. 
However, increase in serum calcium and phosphorus levels was seen 
in all the study subjects. Use of specific anti resorptive drugs like 
bisphosphonates and teriparatide was limited. These factors might 
have long term implications in the treatment of osteoporosis and 
thus need to be addressed. 
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